Triptolide-d3

• Description :

  Triptolide-d3 is the deuterium labeled Triptolide. Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].

• Product Name Alternative :

  PG490-d3

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Isotope-Labeled Compounds; NF-κB

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Apoptosis; NF-κB; Others

• Field of Research :

  Cancer

• Purity :

  91.99

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming)

• Smiles :

  C[C@@]12[C@@]34[C@]5([C@@H]([C@@]6([C@](O6)([H])[C@]3([H])O4)C(C)C)O)[C@@](C[C@@]1([2H])C7=C(C(OC7([2H])[2H])=O)CC2)([H])O5

• Molecular Formula :

  C20H21D3O6

• Molecular Weight :

  363.42

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Ganguly S, et al. Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget. 2015 Oct 13;6 (31) :31767-79.|[3]Huang M, et al. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther. 2013 Feb;12 (2) :184-94.|[4]Xu P, et al. Triptolide Inhibited Cytotoxicity of Differentiated PC12 Cells Induced by Amyloid-Beta25-35 via the Autophagy Pathway. PLoS One. 2015 Nov 10;10 (11) :e0142719.|[5]Kong LL, et al. Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice. Sci Rep. 2015 Jul 2;5:11747.|[6]Zhang W, et al. Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism. Int J Mol Sci. 2016 Dec 19;17 (12) . pii: E2139.|[7]Cai J, et al. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J Exp Clin Cancer Res. 2021;40 (1) :190. Published 2021 Jun 9.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported